Leerink Swann Weighs in on Achaogen Inc’s Q3 2018 Earnings (AKAO)
Achaogen Inc (NASDAQ:AKAO) – Research analysts at Leerink Swann reduced their Q3 2018 earnings per share (EPS) estimates for Achaogen in a report released on Tuesday, August 7th. Leerink Swann analyst A. Fadia now forecasts that the biopharmaceutical company will earn ($0.99) per share for the quarter, down from their previous estimate of ($0.97). Leerink Swann also issued estimates for Achaogen’s Q4 2018 earnings at ($0.75) EPS, FY2018 earnings at ($3.92) EPS, FY2019 earnings at ($2.69) EPS, FY2020 earnings at ($1.78) EPS, FY2021 earnings at ($0.90) EPS and FY2022 earnings at $0.59 EPS.
AKAO has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Cowen reaffirmed a “buy” rating on shares of Achaogen in a research note on Friday, July 27th. BidaskClub raised shares of Achaogen from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Stifel Nicolaus upped their price objective on shares of Achaogen from $14.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective (up previously from $19.00) on shares of Achaogen in a research note on Monday, April 30th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $19.62.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The company had revenue of $2.56 million for the quarter, compared to analyst estimates of $1.49 million.
Large investors have recently modified their holdings of the company. Stifel Financial Corp purchased a new stake in shares of Achaogen during the 1st quarter worth about $134,000. MetLife Investment Advisors LLC purchased a new stake in shares of Achaogen during the 4th quarter worth about $151,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Achaogen during the 1st quarter worth about $207,000. Granite Investment Partners LLC purchased a new stake in shares of Achaogen during the 1st quarter worth about $211,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Achaogen during the 4th quarter worth about $260,000. Institutional investors and hedge funds own 68.74% of the company’s stock.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.